3D Printed Drugs Market: Tablet Segment to Accelerate at a Fast Pace over the Forecast Period 2027

According to The Insight Partners market research study titled “3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019. The market is estimated to grow at a CAGR of 9.1% from 2020 to 2027. The report provides trends prevailing in the 3D printed drug ecosystem, and the driving factors and restraining factors pertaining to the market.

Leading companies operating in the 3D printed drugs market are Aprecia Pharmaceuticals, LLC, FabRx Ltd, Cycle Pharmaceuticals, GlaxoSmithKline PLC., Astrazeneca, Tvasta, and Merck KGGA, among others.

Get sample PDF Copy along with table of content @ https://www.theinsightpartners.com/sample/TIPRE00010199/?utm_source=OpenPR&utm_medium=10144

The global 3D printed drugs market, based on the dosage forms, is segmented into tablets, capsules, multi drug implant, nanoparticles, solutions, and other dosage forms. The tablet segment held the largest share of the market in 2019, and it is further estimated to register the highest CAGR during the forecast period. The growth of the 3D printed drugs market is ascribed to the growing emphasis on personalized medicines and extensive R&D activities.

The global 3D printed drugs market is driven by factors such asincreasing adoption of personalized drugs. Additionally, growing research and development activities,coupled with increasing prevalence of dysphagia,is also anticipated to drive the 3D market growth during the forecast period. However, the usage of 3D printing to develop illegal drugs restrains the growth of the market. The developing healthcare infrastructure and increasing awareness regarding 3D printing in pharmaceuticals generate lucrative opportunities for the growth of the market.

Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, and expect to increase their investment by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the number of personalized medicines in development over the coming five years.

For instance, FabRx Ltd. completed the world’s first in-human clinical study using their proprietary Printlets technology, which relies on personalized 3D printed dosage forms to treat children with a rare metabolic disease. Additionally, the same company launched the first pharmaceutical 3D printer, M3DIMAKER, for the manufacture of personalized medicines in April 2020. Hence, there is a need for new manufacturing systems to prepare personalized medicines, and this potential application of 3D printing for rare diseases is countless. It could help make the medication safer and more attractive to children, thereby propelling the growth of the 3D printed drugs market.

3D Printed Drugs Market – By Dosage Forms

Tablets
Capsules
Multi Drug Implants
Nanoparticles
Solutions
Others
3D Printed Drugs Market – By Technology

Inkjet Printing
Direct Write
Zip Dose
Thermal Inkjet Printing
Fused Deposition Modeling
Powder Bed Printing
Stereolithography (SLA)
Semi Solid Extrusion (SSE)

Place a Purchase Order to Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPRE00010199/?utm_source=OpenPR&utm_medium=10144

Strategic Insights

Product launches and FDA approvalsis a commonly adopted strategy by companies to expand their footprint worldwide and meet the growing demand as the strategy allows them to expand their product portfolios.

The 3D printed drugs marketplayers also adopt the strategy ofcollaborations, which enables them enlarge their global customer base,alongside helping them maintain their brand names.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.